porozendoОстеопороз и остеопатииOsteoporosis and Bone Diseases2072-26802311-0716Endocrinology Research Centre10.14341/osteo13147porozendo-13147Research ArticleНАУЧНЫЕ ОБЗОРЫREVIEWSСовременные представления о механизме действия бисфосфонатов. Влияние длительного приема бисфосфонатов на костную ткань (доклинические исследования)Current vision on mechanism of action of bisphosphonates. The effect of long-term administration of bisphosphonates on bone tissue (preclinical studies)https://orcid.org/0000-0003-4739-4302ТоропцоваН. В.ToroptsovaN. V.

Торопцова Наталья Владимировна - доктор медицинских наук, заведующий лабораторией остеопороза.

Москва

ResearcherID: I-9030-2017; Scopus Author ID: 6507457856

Natalia V. Toroptsova - MD, PhD, head of osteoporosis laboratory.

Moscow

ResearcherID: I-9030-2017; Scopus Author ID: 6507457856

torop@irramn.ruhttps://orcid.org/0000-0002-2469-7346БарановаИ. А.BaranovaI. A.

Баранова Ирина Александровна - д.м.н., профессор, профессор кафедры госпитальной терапии педиатрического факультета.

Москва

ResearcherID: J-3667-2017; Scopus Author ID: 7006313142

Irina A. Baranova - Doctor of Med Sci, Professor.

Moscow

ResearcherID: J-3667-2017; Scopus Author ID: 7006313142

baranova@ro.ruФГБНУ Научно-исследовательский институт ревматологии им. В.А. НасоновойРоссияV.A. Nasonova Research Institute of RheumatologyRussian FederationФГАОУ ВО Российский национальный исследовательский медицинский университет им. Н.И. ПироговаРоссияPirogov Russian National Research Medical UniversityRussian Federation202317032024263411Copyright © Торопцова Н.В., Баранова И.А., 20242024Торопцова Н.В., Баранова И.А.Toroptsova N.V., Baranova I.A.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.osteo-endojournals.ru/jour/article/view/13147

Остеопороз (ОП) — одно из наиболее распространенных хронических заболеваний у лиц пожилого возраста, которое требует продолжительной терапии. Бисфосфонаты (БФ) относятся к препаратам первого выбора для лечения ОП, однако в ходе длительного применения этих препаратов выявлена связь между ними и такими патологическими состояниями, как атипичные переломы бедра, медикаментозный остеонекроз челюсти (МОНЧ), а также рассматриваются вопросы возможного их влияния на процессы консолидации переломов, что привлекает повышенное внимание к текущему широкому их использованию.

В статье представлены существующие классы БФ, различия в их строении и антирезорбтивной активности. Рассматриваются вопросы механизма действия простых и азотсодержащих БФ на кость, а также данные исследований на животных моделях по их влиянию на механические свойства кости, консолидацию переломов, а также развитию МОНЧ.

Osteoporosis (OP) is one of the common chronic diseases in the elderly, which requires long–term therapy. Bisphosphonates (BP) belong to the first-line choice medications for the treatment of OP, however, prolonged period of bisphosphonates use has been associated with increased risk of atypical femoral fractures (AFFs), medication-related osteonecrosis of the jaw (MRONJ) and the impact on fracture healing, which attracts increased attention to the current widespread use of them.

The article presents the existing classes of BP according to their chemical structure and mechanism of action, differences in their antiresorptive potencies. The data of studies on animal models on the effect of BP on the mechanical properties of bone, fracture repair, as well as the development of MRONJ are presented.

остеопорозбисфосфонатыкостный обменремоделированиепреклинические исследованияosteoporosisbisphosphonatesbone turnoverremodelingpreclinical studiesReferencesRussell RG. Bisphosphonates: from bench to bedside. Ann N Y Acad Sci. 2006;1068:367-401. doi: https://doi.org/10.1196/annals.1346.041Russell RG. Bisphosphonates: from bench to bedside. Ann N Y Acad Sci. 2006;1068:367-401. doi: https://doi.org/10.1196/annals.1346.041Fleisch H, Russell RG, Straumann F. Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis. Nature. 1966;212(5065):901-903. doi: https://doi.org/10.1038/212901a0Fleisch H, Russell RG, Straumann F. Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis. Nature. 1966;212(5065):901-903. doi: https://doi.org/10.1038/212901a0Russell RG, Muhlbauer RC, Bisaz S, et al. The influence of pyrophosphate, condensed phosphates, phosphonates and other phosphate compounds on the dissolution of hydroxyapatite in vitro and on bone resorption induced by parathyroid hormone in tissue culture and in thyroparathyroidectomised rats. Calcif Tissue. Res. 1970;6(3):183-196. doi: https://doi.org/10.1007/BF02196199Russell RG, Muhlbauer RC, Bisaz S, et al. The influence of pyrophosphate, condensed phosphates, phosphonates and other phosphate compounds on the dissolution of hydroxyapatite in vitro and on bone resorption induced by parathyroid hormone in tissue culture and in thyroparathyroidectomised rats. Calcif Tissue. Res. 1970;6(3):183-196. doi: https://doi.org/10.1007/BF02196199Plotkin LI, Aguirre JI, Kousteni S, et al. Bisphosphonates and estrogens inhibit osteocyte apoptosis via distinct molecular mechanisms downstream of extracellular signal-regulated kinase activation. J Biol Chem. 2005; 280:7317-7325. doi: https://doi.org/10.1074/jbc.M412817200Plotkin LI, Aguirre JI, Kousteni S, et al. Bisphosphonates and estrogens inhibit osteocyte apoptosis via distinct molecular mechanisms downstream of extracellular signal-regulated kinase activation. J Biol Chem. 2005; 280:7317-7325. doi: https://doi.org/10.1074/jbc.M412817200Bellido T, Plotkin LI. Novel actions of bisphosphonates in bone: preservation of osteoblast and osteocyte viability. Bone. 2011 Jul;49(1):50-5. doi: https://doi.org/0.1016/j.bone.2010.08.008Bellido T, Plotkin LI. Novel actions of bisphosphonates in bone: preservation of osteoblast and osteocyte viability. Bone. 2011 Jul;49(1):50-5. doi: https://doi.org/0.1016/j.bone.2010.08.008Rogers MJ, Monkkonen J, Munoz MA. Molecular mechanisms of action of bisphosphonates and new insights into their effects outside the skeleton. Bone. 2020, Volume 139, 115493. doi: https://doi.org/10.1016/j.bone.2020.115493Rogers MJ, Monkkonen J, Munoz MA. Molecular mechanisms of action of bisphosphonates and new insights into their effects outside the skeleton. Bone. 2020, Volume 139, 115493. doi: https://doi.org/10.1016/j.bone.2020.115493Papapoulos SE, Cremers SC. Prolonged bisphosphonate release after treatment in children. N Engl J Med. 2007;356(10):1075-1076. doi: https://doi.org/10.1056/NEJMc062792Papapoulos SE, Cremers SC. Prolonged bisphosphonate release after treatment in children. N Engl J Med. 2007;356(10):1075-1076. doi: https://doi.org/10.1056/NEJMc062792Dunford JE, Thompson K, Coxon FP, et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001;296(2):235-242Dunford JE, Thompson K, Coxon FP, et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001;296(2):235-242Kavanagh KL, Guo K, Dunford JE, et al. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci U S A. 2006 May 16;103(20):7829-7834. doi: https://doi.org/10.1073/pnas.0601643103Kavanagh KL, Guo K, Dunford JE, et al. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci U S A. 2006 May 16;103(20):7829-7834. doi: https://doi.org/10.1073/pnas.0601643103Itzstein C, Coxon FP, Rogers MJ. The regulation of osteoclast function and bone resorption by small GTPases. Small GTPases. 2011;2 (3):117-130. doi: https://doi.org/10.4161/sgtp.2.3.16453Itzstein C, Coxon FP, Rogers MJ. The regulation of osteoclast function and bone resorption by small GTPases. Small GTPases. 2011;2 (3):117-130. doi: https://doi.org/10.4161/sgtp.2.3.16453Monkkonen H, Auriola S, Lehenkari P, et al. A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates. Br J Pharmacol. 2006;147(4):437-45. doi: https://doi.org/10.1038/sj.bjp.0706628Monkkonen H, Auriola S, Lehenkari P, et al. A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates. Br J Pharmacol. 2006;147(4):437-45. doi: https://doi.org/10.1038/sj.bjp.0706628Halasy-Nagy JM, Rodan GA, Reszka AA. Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis. Bone. 2001;29(6):553-559. doi: https://doi.org/10.1016/s8756-3282(01)00615-9Halasy-Nagy JM, Rodan GA, Reszka AA. Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis. Bone. 2001;29(6):553-559. doi: https://doi.org/10.1016/s8756-3282(01)00615-9Van Beek ER, Lowik CWGM, Papapoulos SE. Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: the role of protein geranylgeranylation in the action of nitrogencontaining bisphosphonates on osteoclast precursors. Bone. 2002;30(1):64-70. doi: https://doi.org/10.1016/S8756-3282(01)00655-XVan Beek ER, Lowik CWGM, Papapoulos SE. Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: the role of protein geranylgeranylation in the action of nitrogencontaining bisphosphonates on osteoclast precursors. Bone. 2002;30(1):64-70. doi: https://doi.org/10.1016/S8756-3282(01)00655-XThompson K, Dunford JE, Ebetino FH, Rogers MJ. Identification of a bisphosphonate that inhibits isopentenyl diphosphate isomerase and farnesyl diphosphate synthase. Biochem. Biophys. Res. Commun. 2002;290(2):869-873. doi: https://doi.org/10.1006/bbrc.2001.6289Thompson K, Dunford JE, Ebetino FH, Rogers MJ. Identification of a bisphosphonate that inhibits isopentenyl diphosphate isomerase and farnesyl diphosphate synthase. Biochem. Biophys. Res. Commun. 2002;290(2):869-873. doi: https://doi.org/10.1006/bbrc.2001.6289Kavanagh KL, Dunford JE, Bunkoczi G, et al. The crystal structure of human geranylgeranyl pyrophosphate synthase reveals a novel hexameric arrangement and inhibitory product binding. J. Biol. Chem. 2006;281(31):22004-22012. doi: https://doi.org/10.1074/jbc.M602603200Kavanagh KL, Dunford JE, Bunkoczi G, et al. The crystal structure of human geranylgeranyl pyrophosphate synthase reveals a novel hexameric arrangement and inhibitory product binding. J. Biol. Chem. 2006;281(31):22004-22012. doi: https://doi.org/10.1074/jbc.M602603200Amin D, Cornell SA, Perrone M.H, Bilder G.E. 1-Hydroxy-3-(methylpentylamino)-propylidene-1,1-bisphosphonic acid as a potent inhibitor of squalene synthase. Arzneimittel-Forschung. 1996;46(8):759-762Amin D, Cornell SA, Perrone M.H, Bilder G.E. 1-Hydroxy-3-(methylpentylamino)-propylidene-1,1-bisphosphonic acid as a potent inhibitor of squalene synthase. Arzneimittel-Forschung. 1996;46(8):759-762Allen MR. Recent Advances in Understanding Bisphosphonate Effects on Bone Mechanical Properties. Curr Osteoporos Rep. Apr 2018;16(2):198-204. doi: https://doi.org/10.1007/s11914-018-0430-3Allen MR. Recent Advances in Understanding Bisphosphonate Effects on Bone Mechanical Properties. Curr Osteoporos Rep. Apr 2018;16(2):198-204. doi: https://doi.org/10.1007/s11914-018-0430-3Balena R, Markatos A, Seedor JG, et al. Long-term safety of the aminobisphosphonate alendronate in adult dogs. II. Histomorphometric analysis of the L5 vertebrae. J Pharmacol Exp Ther. Jan 1996;276(1):277-83Balena R, Markatos A, Seedor JG, et al. Long-term safety of the aminobisphosphonate alendronate in adult dogs. II. Histomorphometric analysis of the L5 vertebrae. J Pharmacol Exp Ther. Jan 1996;276(1):277-83Mashiba T, Turner CH, Hirano T, et al. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone. May 2001;28(5):524-31. doi: https://doi.org/10.1016/s8756-3282(01)00414-8Mashiba T, Turner CH, Hirano T, et al. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone. May 2001;28(5):524-31. doi: https://doi.org/10.1016/s8756-3282(01)00414-8Mashiba T, Hirano T, Turner CH, et al. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res. Apr 2000;15(4):613-20. doi: https://doi.org/10.1359/jbmr.2000.15.4.613Mashiba T, Hirano T, Turner CH, et al. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res. Apr 2000;15(4):613-20. doi: https://doi.org/10.1359/jbmr.2000.15.4.613Allen MR, Reinwald S, Burr DB. Alendronate reduces bone toughness of ribs without significantly increasing microdamage accumulation in dogs following 3 years of daily treatment. Calcif Tissue Int. May 2008;82(5):354-60. doi: https://doi.org/10.1007/s00223-008-9131-8Allen MR, Reinwald S, Burr DB. Alendronate reduces bone toughness of ribs without significantly increasing microdamage accumulation in dogs following 3 years of daily treatment. Calcif Tissue Int. May 2008;82(5):354-60. doi: https://doi.org/10.1007/s00223-008-9131-8Allen MR, Burr DB. Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment. J Bone Miner Res. Nov 2007;22(11):1759-65. doi: https://doi.org/10.1359/jbmr.070720Allen MR, Burr DB. Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment. J Bone Miner Res. Nov 2007;22(11):1759-65. doi: https://doi.org/10.1359/jbmr.070720Burr DB, Diab T, Koivunemi A, et al. Effects of 1 to 3 years' treatment with alendronate on mechanical properties of the femoral shaft in a canine model: implications for subtrochanteric femoral fracture risk. J Orthop Res. Oct 2009;27(10):1288-92. doi: https://doi.org/10.1002/jor.20895Burr DB, Diab T, Koivunemi A, et al. Effects of 1 to 3 years' treatment with alendronate on mechanical properties of the femoral shaft in a canine model: implications for subtrochanteric femoral fracture risk. J Orthop Res. Oct 2009;27(10):1288-92. doi: https://doi.org/10.1002/jor.20895Bajaj D, Geissler JR, Allen MR, et al. The resistance of cortical bone tissue to failure under cyclic loading is reduced with alendronate. Bone. Jul 2014;64:57-64. doi: https://doi.org/10.1016/j.bone.2014.03.045Bajaj D, Geissler JR, Allen MR, et al. The resistance of cortical bone tissue to failure under cyclic loading is reduced with alendronate. Bone. Jul 2014;64:57-64. doi: https://doi.org/10.1016/j.bone.2014.03.045Acevedo C, Bale H, Gludovatz B, et al. Alendronate treatment alters bone tissues at multiple structural levels in healthy canine cortical bone. Bone. Dec 2015;81:352-363. doi: https://doi.org/10.1016/j.bone.2015.08.002Acevedo C, Bale H, Gludovatz B, et al. Alendronate treatment alters bone tissues at multiple structural levels in healthy canine cortical bone. Bone. Dec 2015;81:352-363. doi: https://doi.org/10.1016/j.bone.2015.08.002Larsson S, Fazzalari NL. Anti-osteoporosis therapy and fracture healing. Arch Orthop Trauma Surg. Feb 2014;134(2):291-7. doi: https://doi.org/10.1007/s00402-012-1558-8Larsson S, Fazzalari NL. Anti-osteoporosis therapy and fracture healing. Arch Orthop Trauma Surg. Feb 2014;134(2):291-7. doi: https://doi.org/10.1007/s00402-012-1558-8Kates SL, Ackert-Bicknell CL. How do bisphosphonates affect fracture healing? Injury. Jan 2016;47 Suppl 1(0 1):S65-8. doi: https://doi.org/10.1016/S0020-1383(16)30015-8Kates SL, Ackert-Bicknell CL. How do bisphosphonates affect fracture healing? Injury. Jan 2016;47 Suppl 1(0 1):S65-8. doi: https://doi.org/10.1016/S0020-1383(16)30015-8Gorter EA, Reinders CR, Krijnen P, et al. The effect of osteoporosis and its treatment on fracture healing a systematic review of animal and clinical studies. Bone Rep. Dec 2021;15:101117. doi: https://doi.org/10.1016/j.bonr.2021.101117Gorter EA, Reinders CR, Krijnen P, et al. The effect of osteoporosis and its treatment on fracture healing a systematic review of animal and clinical studies. Bone Rep. Dec 2021;15:101117. doi: https://doi.org/10.1016/j.bonr.2021.101117Begkas D, Pastroudis A, Touzopoulos P, et al. The Effects of Long-term Use of Nitrogen-containing Bisphosphonates on Fracture Healing. Cureus. Mar 25 2019;11(3):e4307. doi: https://doi.org/10.7759/cureus.4307Begkas D, Pastroudis A, Touzopoulos P, et al. The Effects of Long-term Use of Nitrogen-containing Bisphosphonates on Fracture Healing. Cureus. Mar 25 2019;11(3):e4307. doi: https://doi.org/10.7759/cureus.4307Kidd LJ, Cowling NR, Wu AC, et al. Bisphosphonate treatment delays stress fracture remodeling in the rat ulna. J Orthop Res. Dec 2011;29(12):1827-33. doi: https://doi.org/10.1002/jor.21464Kidd LJ, Cowling NR, Wu AC, et al. Bisphosphonate treatment delays stress fracture remodeling in the rat ulna. J Orthop Res. Dec 2011;29(12):1827-33. doi: https://doi.org/10.1002/jor.21464Amanat N, McDonald M, Godfrey C, et al. Optimal timing of a single dose of zoledronic acid to increase strength in rat fracture repair. J Bone Miner Res. Jun 2007;22(6):867-76. doi: https://doi.org/10.1359/jbmr.070318Amanat N, McDonald M, Godfrey C, et al. Optimal timing of a single dose of zoledronic acid to increase strength in rat fracture repair. J Bone Miner Res. Jun 2007;22(6):867-76. doi: https://doi.org/10.1359/jbmr.070318Allen MR, Aref MW. What Animal Models Have Taught Us About the Safety and Efficacy of Bisphosphonates in Chronic Kidney Disease. Curr Osteoporos Rep. Jun 2017;15(3):171-177. doi: https://doi.org/10.1007/s11914-017-0361-4Allen MR, Aref MW. What Animal Models Have Taught Us About the Safety and Efficacy of Bisphosphonates in Chronic Kidney Disease. Curr Osteoporos Rep. Jun 2017;15(3):171-177. doi: https://doi.org/10.1007/s11914-017-0361-4Damasiewicz MJ, Nickolas TL. Bisphosphonate therapy in CKD: the current state of affairs. Curr Opin Nephrol Hypertens. Mar 2020;29(2):221-226. doi: https://doi.org/10.1097/MNH.0000000000000585MDamasiewicz MJ, Nickolas TL. Bisphosphonate therapy in CKD: the current state of affairs. Curr Opin Nephrol Hypertens. Mar 2020;29(2):221-226. doi: https://doi.org/10.1097/MNH.0000000000000585MAllen MR, Chen NX, Gattone VH, et al. Skeletal effects of zoledronic acid in an animal model of chronic kidney disease. Osteoporos Int. Apr 2013;24(4):1471-81. doi: https://doi.org/10.1007/s00198-012-2103-xAllen MR, Chen NX, Gattone VH, et al. Skeletal effects of zoledronic acid in an animal model of chronic kidney disease. Osteoporos Int. Apr 2013;24(4):1471-81. doi: https://doi.org/10.1007/s00198-012-2103-xMoe SM, Chen NX, Newman CL, et al. A comparison of calcium to zoledronic acid for improvement of cortical bone in an animal model of CKD. J Bone Miner Res. Apr 2014;29(4):902-10. doi: https://doi.org/10.1002/jbmr.2089Moe SM, Chen NX, Newman CL, et al. A comparison of calcium to zoledronic acid for improvement of cortical bone in an animal model of CKD. J Bone Miner Res. Apr 2014;29(4):902-10. doi: https://doi.org/10.1002/jbmr.2089Aguirre JI, Castillo EJ, Kimmel DB. Preclinical models of medication-related osteonecrosis of the jaw (MRONJ). Bone. Dec 2021;153:116184. doi: https://doi.org/10.1016/j.bone.2021.116184Aguirre JI, Castillo EJ, Kimmel DB. Preclinical models of medication-related osteonecrosis of the jaw (MRONJ). Bone. Dec 2021;153:116184. doi: https://doi.org/10.1016/j.bone.2021.116184Tetradis S, Allen MR, Ruggiero SL. Pathophysiology of Medication-Related Osteonecrosis of the Jaw-A Minireview. JBMR Plus. Aug 2023;7(8):e10785. doi: https://doi.org/10.1002/jbm4.10785Tetradis S, Allen MR, Ruggiero SL. Pathophysiology of Medication-Related Osteonecrosis of the Jaw-A Minireview. JBMR Plus. Aug 2023;7(8):e10785. doi: https://doi.org/10.1002/jbm4.10785

The authors declare that there are no conflicts of interest present.